The federal Food and Drug Administration is considering approving a new Parkinson’s drug that could offer patients a “second honeymoon” in terms of controlling their motor symptoms.
AbbVie Pharmaceuticals has submitted a New Drug Application (NDA) to the federal Food and Drug Administration for the first novel drug treatment for Parkinson’s disease in more than half a century. The drug tavapadon selectively activates a brain target called the D1 dopamine receptor. Its potential as a new treatment for Parkinson’s disease and other disorders was pioneered by University of Virginia School of Medicine Professor of Pharmacology and Neuroscience Richard B. Mailman, PhD.
please visit this official website more information about Parkinson’s Disease: symptoms, how to diagnose and treat it..God help you..
